Probiotic Treatment for Huntington's Disease?
- Conditions
- Huntington's DiseaseNeurological - Neurodegenerative diseases
- Registration Number
- ACTRN12618000102279
- Lead Sponsor
- Monash University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 84
Healthy control and Huntington's disease participants aged 18-70 will be eligible barring they do not violate any of the exclusion criteria.
Exclusion criteria for all participants includes; diagnosis of any other major neurological disorder, traumatic brain injury, drug or alcohol dependency (in the last 3 months), recent diagnosis of major depression or psychosis, consumption of oral antibiotics (in the past 6 months), high daily consumption of probiotic or fermented foods (foods preserved in high amounts of bacteria) within six weeks prior to the study. Further exclusion includes hospitalised patients with a central venous catheter, people with allergies to yeast, people with a diagnosis of Irritable Bowel Syndrome, Celiac's disease or Crohn's disease and people who are severely ill and/or immunocompromised.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome will be HD-CAB Composite Scores (i.e., composite scores of the Symbol Digits Modalities Task; Paced Tapping; One Touch Stockings; Emotion Recognition; Trail Making Test B; Hopkins Verbal Learning Test). <br><br>These scores will be calculated for the HD and control groups.[Participants will be assessed twice (once at baseline and again 6-weeks later).]
- Secondary Outcome Measures
Name Time Method Quality of life, as measured by HDQLIFE score.[Participants will be assessed twice (once at baseline and again 6-weeks later).];Gut Microbiome Analysis - as measured by levels of bacteria in the gut.<br>[Participants will be assessed twice (once at baseline and again 6-weeks later).]